Drug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.
Chris Smyth, PhD
Advertisement
Articles by Chris Smyth, PhD
Gene-editing technology has the ability to give oncology researchers an effective treatment option in the fight against cancer. CRISPR-Cas9 is such a technology that is currently being used to study genes in cancer cells.
Applied Clinical Trials
The smaller biopharmaceutical company perspective on mastering oncology immunotherapy clinical trials.
Advertisement
Latest Updated Articles
Imagining the Impossible: Immunity to CancerApril 1st 2016
- Harnessing CRISPR-Cas9 within Oncology Clinical Research
September 29th 2016
- Developing New Clinical Endpoints for Immuno-Oncology Studies
February 23rd 2017
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
2
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
3
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
4
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
5